Novoseven 1 mg Injection 1's

Novoseven 1 mg Injection belongs to the class of antihemophilic medicine. It is primarily used to prevent excessive bleeding after surgery or other important treatments, especially in patients with congenital hemophilia who do not respond to factor VIII or IX treatment, acquired hemophilia, factor VII deficiency, and Glanzmann’s thrombosthenia.

Novoseven 1 mg Injection contains Eptacog alfa (activated), which is an antihemophilic drug. It helps clot the bleeding when our body’s clotting factors do not respond.

Novoseven 1 mg Injection may cause certain side effects such as headache, nausea, vomiting, fatigue, fever, flushing (sense of warmth) of the face, fast or irregular heart rate, low blood pressure, and redness, pain, or swelling at the injection site. These side effects may not occur in everyone using this medication and gradually resolve over time. Novoseven 1 mg Injection will be administered by a trained healthcare doctor.

Before starting Novoseven 1 mg Injection, inform your doctor if you have any allergies to the components present in it. Let your doctor know about your complete medical and medication history to rule out any serious adverse effects. Inform your doctor, if you have any history of liver or kidney disease, a recent history of surgery or crush injury, atherosclerosis, or bleeding disorder. Pregnant and breastfeeding women should consult their doctor before using Novoseven 1 mg Injection.

Novoseven 1 mg Injection is used in the treatment of Hemophilia A and Glanzmann’s thrombasthenia. The detailed uses of Novoseven 1 mg Injection are as follows:

• Treatment of Bleeding Episodes in Hemophilia: Novoseven 1 mg Injection is used to control bleeding in patients with congenital hemophilia A or B who have developed inhibitors against factor VIII or IX.
• Management of Acquired Hemophilia and Factor VII Deficiency:Novoseven 1 mg Injection helps promote clotting in individuals with acquired hemophilia or inherited factor VII deficiency when standard therapies are ineffective.
• Support in Glanzmann’s Thrombasthenia: Novoseven 1 mg Injection is used for patients with Glanzmann’s thrombasthenia who do not respond to platelet transfusions, aiding in hemostasis during surgical or spontaneous bleeding.
• Activation of Coagulation Cascade: Novoseven 1 mg Injection works by activating factor X and IX, leading to thrombin generation and fibrin clot formation, even when natural clotting factors are deficient or inhibited.

• Novoseven 1 mg Injection will be administered by a healthcare professional.
• If self-administration is advised, ask your doctor for complete information regarding the reconstitution of the medicine and its administration.

Novoseven 1 mg Injection is a blood coagulation medicine that helps with blood clotting. It mainly works by increasing the plasma levels of factor VIII activity in patients with hemophilia and thereby helps clot the bleeding when our body’s clotting factors do not respond.

To treat your condition effectively, continue receiving Novoseven 1 mg Injection for the period that your doctor has prescribed. Discontinue the medicine and inform your doctor if you observe any allergic reactions after receiving Novoseven 1 mg Injection. Please consult your doctor before starting the treatment if you are pregnant, planning to conceive, or are a breastfeeding mother. Novoseven 1 mg Injection should be used in children only when prescribed by the doctor. This medicine may cause severe thromboembolic events. Hence, inform your doctor if you have any history of liver or kidney disease, heart problems or failure, a recent history of surgery or crush injury, atherosclerosis, thrombosis, or severe bleeding disorder. This medicine is contraindicated for patients who are allergic to mouse, hamster, or cow proteins.